v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
Note 14 – Segment Reporting


In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy. The financial results of the Company’s operations are managed and reported to the Chief Executive Officer who is considered the Company’s chief operating decision maker (CODM), on a consolidated basis.


The CODM assesses performance and allocates resources based on the Company’s consolidated statements of operations and key components and processes of the Company’s operations are managed centrally. Segment asset information is not used by the CODM to allocate resources.


As a single reportable segment entity, the Company’s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:

   
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2026
    
2025
     2026
    2025
 
Segment expenses
                        
Salaries and Benefits
  
$
3,377,524
    
$
2,857,617
     $ 6,775,882     $ 6,686,838  
Professional fees
    
1,111,476
      
1,278,581
       2,018,160       2,405,627  
General administrative expenses
    
309,370
      
387,897
       651,869       732,251  
Clinical development expenses
    
1,084,716
      
2,017,145
       2,353,900       2,455,049  
Other development expenses
    
613,648
      
1,082,111
       1,218,010       4,449,344  
Total operating and segment expenses
  
$
6,496,734
     $ 7,623,351     $ 13,017,821     $ 16,729,109  
                                 
Interest income
    
125,405
      
333,624
       312,219       711,473  
Interest expense
    
(3,379,246
)
    
(2,144,481
)
     (4,394,029 )     (3,075,359 )
Benefit from income taxes
    
-
      
-
       -       1,169,820  
Segment and consolidated net loss
  
$
(9,750,575
)
  
$
(9,434,208
)
   $ (17,099,631 )   $ (17,923,175 )